Condensed Consolidated Interim Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
REVENUES:
Total revenues	$ 40,971	$ 34,141
COST OF REVENUES:
Total cost of revenues	13,302	10,983
Gross profit	27,669	23,158
OPERATING EXPENSES:
General and administrative	14,473	22,295
Sales and marketing	4,086	8,432
Technology and development	4,431	4,802
Total operating expenses	22,990	35,529
Income (loss) from operations	4,679	(12,371)
NON-OPERATING INCOME (EXPENSE):
Other income (expense)	411	(3)
Total non-operating income (expense)	411	(3)
Income (loss) before income taxes	5,090	(12,374)
Income taxes	396	150
Net income (loss)	4,694	(12,524)
Net income (loss) attributable to non-controlling interests	1,749	(5,259)
Net income (loss) attributable to Enfusion, Inc.	$ 2,945	$ (7,265)
Net income (loss) per Class A common shares attributable to Enfusion, Inc.:
Net income (loss) per share of Class A common stock--Basic	$ 0.04	$ (0.10)
Net income (loss) per share of Class A common stock--Diluted	$ 0.04	$ (0.10)
Weighted Average number of Class A common shares outstanding:
Weighted Average number of Class A common shares outstanding, Basic	88,863	83,384
Weighted Average number of Class A common shares outstanding, Diluted	132,346	83,384
Platform subscriptions
REVENUES:
Total revenues	$ 37,998	$ 31,551
COST OF REVENUES:
Total cost of revenues	11,675	9,311
Managed services
REVENUES:
Total revenues	2,744	2,230
COST OF REVENUES:
Total cost of revenues	1,564	1,615
Other
REVENUES:
Total revenues	229	360
COST OF REVENUES:
Total cost of revenues	$ 63	$ 57